Patents by Inventor Michael P. Arend

Michael P. Arend has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity
    Patent number: 8952160
    Abstract: The present invention relates to novel compounds according to Formula I or II, methods, and compositions capable of decreasing HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF). Formula (I) or (II).
    Type: Grant
    Filed: January 12, 2009
    Date of Patent: February 10, 2015
    Assignee: Fibrogen, Inc.
    Inventors: Xiaoti Zhou, Michael P. Arend, Min Wu, Lee A. Flippin
  • 4 -HYDROXY- ISOQUINOLINE COMPOUNDS AS HIF HYDROXYLASE INHIBITORS
    Publication number: 20150038528
    Abstract: The present invention relates to novel compounds of formula (I), and compositions capable of inhibiting PHD1 enzyme activity selectively over other isoforms, for example, PHD2 and/or PHD3 enzymes. The invention also relates to compounds of formula (I) for use in disorders such as muscle degeneration, colitis, IBD, and certain ischemias.
    Type: Application
    Filed: March 8, 2013
    Publication date: February 5, 2015
    Inventors: Wen-Bin Ho, Hongda Zhao, Shaojiang Deng, Danny Ng, Lee R. Wright, Min Wu, Xiaoti Zhou, Michael P. Arend, Lee A. Flippin
  • CRYSTALLINE FORMS OF A PROLYL HYDROXYLASE INHIBITOR
    Publication number: 20150038529
    Abstract: The present disclosure relates to crystalline solid forms of [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid, the process of preparing the forms, and pharmaceutical compositions and methods of use thereof.
    Type: Application
    Filed: October 21, 2014
    Publication date: February 5, 2015
    Inventors: Claudia Witschi, Jung Min Park, Michael D. Thompson, Michael John Martinelli, David A. Yeowell, Michael P. Arend
  • Naphthyridine derivatives as inhibitors of hypoxia inducible factor (HIF) hydroxylase
    Patent number: 8921389
    Abstract: The present disclosure relates to novel compounds, methods, and compositions capable of inhibiting HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF).
    Type: Grant
    Filed: February 1, 2012
    Date of Patent: December 30, 2014
    Assignee: Fibrogen, Inc.
    Inventors: Danny Ng, Michael P. Arend, Lee A. Flippin
  • Nitrogen-containing heteroaryl compounds and methods of use thereof
    Patent number: 8916585
    Abstract: The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.
    Type: Grant
    Filed: August 30, 2012
    Date of Patent: December 23, 2014
    Assignee: Fibrogen, Inc.
    Inventors: Michael P. Arend, Lee A. Flippin, Volkmar Guenzler-Pukall, Wen-Bin Ho, Eric D. Turtle, Xiaohui Du
  • NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20140343094
    Abstract: The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.
    Type: Application
    Filed: May 21, 2014
    Publication date: November 20, 2014
    Inventors: Michael P. Arend, Lee A. Flippin, Volkmar Guenzler-Pukall, Wen-Bin Ho, Eric D. Turtle, Xiaohui Du
  • Crystalline forms of a prolyl hydroxylase inhibitor
    Patent number: 8883823
    Abstract: The present disclosure relates to crystalline solid forms of [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid, the process of preparing the forms, and pharmaceutical compositions and methods of use thereof.
    Type: Grant
    Filed: July 15, 2013
    Date of Patent: November 11, 2014
    Assignee: FibroGen, Inc.
    Inventors: Claudia Witschi, Jung Min Park, Michael D. Thompson, Michael John Martinelli, David A. Yeowell, Michael P. Arend
  • CRYSTALLINE FORMS OF A PROLYL HYDROXYLASE INHIBITOR
    Publication number: 20140303202
    Abstract: The present disclosure relates to crystalline solid forms of [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid, the process of preparing the forms, and pharmaceutical compositions and methods of use thereof.
    Type: Application
    Filed: July 15, 2013
    Publication date: October 9, 2014
    Inventors: Claudia Witschi, Jung Min Park, Michael D. Thompson, Michael John Martinelli, David A. Yeowell, Michael P. Arend
  • NOVEL THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF
    Publication number: 20140221422
    Abstract: The present invention relates to novel compounds capable of modulating the stability and/or activity of hypoxia inducible factor (HIF).
    Type: Application
    Filed: April 9, 2014
    Publication date: August 7, 2014
    Applicant: FIBROGEN, INC.
    Inventors: Eric D. Turtle, Lee A. Flippin, Michael P. Arend, Heng Cheng
  • Nitrogen-containing heteroaryl compounds and methods of use thereof
    Patent number: 8765956
    Abstract: The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.
    Type: Grant
    Filed: June 7, 2013
    Date of Patent: July 1, 2014
    Assignee: Fibrogen, Inc.
    Inventors: Michael P. Arend, Lee A. Flippin, Volkmar Guenzler-Pukall, Wen-Bin Ho, Eric D. Turtle, Xiaohui Du
  • Cyanoisoquinoline compounds and methods of use thereof
    Patent number: 8759373
    Abstract: The present invention relates to cyanoisoquinoline compounds suitable for use in treating hypoxia inducible factor-mediated and/or erythropoietin-associated conditions.
    Type: Grant
    Filed: March 26, 2012
    Date of Patent: June 24, 2014
    Assignee: Fibrogen, Inc.
    Inventors: Michael P. Arend, Lee A. Flippin, Min Wu, Eric D. Turtle, Wen-Bin Ho, Shaojiang Deng
  • Thienopyridine compounds, and methods of use thereof
    Patent number: 8703795
    Abstract: The present invention relates to novel compounds capable of modulating the stability and/or activity of hypoxia inducible factor (HIF).
    Type: Grant
    Filed: March 2, 2006
    Date of Patent: April 22, 2014
    Assignee: Fibrogen, Inc.
    Inventors: Eric D. Turtle, Lee A. Flippin, Michael P. Arend, Heng Cheng
  • NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF HYPOXIA INDUCIBLE FACTOR (HIF) HYDROXYLASE
    Publication number: 20140088101
    Abstract: The present disclosure relates to novel compounds, methods, and compositions capable of inhibiting HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF).
    Type: Application
    Filed: February 1, 2012
    Publication date: March 27, 2014
    Applicant: FibroGen, Inc.
    Inventors: Danny Ng, Michael P. Arend, Lee A. Flippin
  • CRYSTALLINE FORMS OF A PROLYL HYDROXYLASE INHIBITOR
    Publication number: 20140024676
    Abstract: The present disclosure relates to crystalline solid forms of [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid, the process of preparing the forms, and pharmaceutical compositions and methods of use thereof.
    Type: Application
    Filed: July 15, 2013
    Publication date: January 23, 2014
    Inventors: Claudia Witschi, Jung Min Park, Michael D. Thompson, Michael John Martinelli, David A. Yeowell, Michael P. Arend
  • CRYSTALLINE FORMS OF A PROLYL HYDROXYLASE INHIBITOR
    Publication number: 20140024675
    Abstract: The present disclosure relates to crystalline solid forms of [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid, the process of preparing the forms, and pharmaceutical compositions and methods of use thereof.
    Type: Application
    Filed: July 15, 2013
    Publication date: January 23, 2014
    Inventors: Claudia Witschi, Jung Min Park, Michael D. Thompson, Michael John Martinelli, David A. Yeowell, Michael P. Arend
  • NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20130310565
    Abstract: The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.
    Type: Application
    Filed: June 7, 2013
    Publication date: November 21, 2013
    Inventors: Michael P. Arend, Lee A. Flippin, Volkmar Guenzler-Pukall, Wen-Bin Ho, Eric D. Turtle, Xiaohui Du
  • Stabilization of Hypoxia Inducible Factor (HIF) Alpha
    Publication number: 20130245037
    Abstract: The present invention relates to methods of stabilizing the alpha subunit of hypoxia inducible factor (HIF). The invention further relates to methods of preventing, pretreating, or treating conditions associated with HIF, including ischemic and hypoxic conditions. Compounds for use in these methods are also provided.
    Type: Application
    Filed: May 17, 2013
    Publication date: September 19, 2013
    Applicant: FibroGen, Inc.
    Inventors: Volkmar Guenzler-Pukall, Thomas B. Neff, Qingjian Wang, Michael P. Arend, Lee A. Flippin, Alex Melekhov
  • Methods for treating anemia using inhibitors of hypoxia-inducible factor (HIF) hydroxylase
    Publication number: 20130203805
    Abstract: The present invention relates to methods for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo. Methods for treating, pretreating or preconditioning, or preventing erythropoietin-associated conditions are also included. Compounds for use in these methods are provided, as are methods of identifying such compounds.
    Type: Application
    Filed: September 13, 2012
    Publication date: August 8, 2013
    Applicant: FIBROGEN, INC.
    Inventors: Stephen J. Klaus, Al Y. Lin, Thomas B. Neff, Qingjian Wang, Volkmar Guenzler-Pukall, Michael P. Arend, Lee A. Flippin, Alex Melekhov
  • NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20130178417
    Abstract: The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.
    Type: Application
    Filed: August 30, 2012
    Publication date: July 11, 2013
    Inventors: Michael P. AREND, Lee A. FLIPPIN, Volkmar GUENZLER-PUKALL, Wen-Bin HO, Eric D. TURTLE, Xiaohui DU
  • Stabilization of hypoxia inducible factor (HIF) alpha
    Patent number: 8466172
    Abstract: The present invention relates to methods of stabilizing the alpha subunit of hypoxia inducible factor (HIF). The invention further relates to methods of preventing, pretreating, or treating conditions associated with HIF, including ischemic and hypoxic conditions. Compounds for use in these methods are also provided.
    Type: Grant
    Filed: December 2, 2010
    Date of Patent: June 18, 2013
    Assignee: FibroGen, Inc.
    Inventors: Volkmar Guenzler-Pukall, Thomas B. Neff, Qingjian Wang, Michael P. Arend, Lee A. Flippin, Alex Melekhov